A diagnostic kit and diagnostic system for nonalcoholic fatty hepatitis

By discovering and analyzing characteristic genes of tertiary lymphatic structure in NASH liver tissue, constructing specific gene sets, and developing diagnostic kits and systems, the problem of difficulty in accurately quantifying existing NASH diagnostic methods is solved, and the degree of progress of NASH is achieved The accurate quantitative diagnosis improves the specificity and sensitivity of the diagnosis.

CN118547066BActive Publication Date: 2024-11-19RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411027274.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-07-30
Publication Date
2024-11-19
Estimated Expiration
2044-07-30

AI Technical Summary

Technical Problem

The existing NASH diagnostic methods rely on naked eye observation, are difficult to accurately quantify, and early diagnosis is difficult to achieve, and there is a lack of effective diagnostic tools.

Method used

Through high-resolution section scanning, H&E staining and multicolor immunofluorescence staining, tertiary lymphoid structures in NASH liver tissue were discovered, 12 characteristic genes were screened, NASH-specific TLS gene sets were constructed, and diagnostic kits and systems were developed. Quantitative diagnosis was performed using spatial transcriptome sequencing and bioinformatic analysis.

Benefits of technology

Accurate quantitative diagnosis of the degree of NASH progress is achieved, the specificity and sensitivity of the diagnosis is improved, and a reliable auxiliary diagnostic tool has good clinical application potential.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118547066B_ABST
    Figure CN118547066B_ABST
Patent Text Reader

Abstract

The purpose of the present invention is to achieve the quantification and reliable diagnosis of non-alcoholic fatty hepatitis, and a diagnostic kit for non-alcoholic fatty hepatitis is provided, characterized in that it at least includes a detection object for detecting a characteristic tertiary lymphoid structure gene set of non-alcoholic fatty hepatitis, wherein the characteristic tertiary lymphoid structure gene set of non-alcoholic fatty hepatitis includes the following 12 characteristic genes: IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6 and IGHG3. The present invention also provides a diagnostic system containing the diagnostic kit.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the field of medical equipment, and in particular relates to a diagnostic kit for non-alcoholic fatty hepatitis. Background Art

[0002] Due to changes in dietary structure and living habits brought about by economic development, the incidence of non-alcoholic fatty liver disease (NAFLD) is rapidly increasing worldwide, seriously endangering human health.

[0003] Nonalcoholic steatohepatitis (NASH) is a chronic inflammatory disease closely related to diseases such as obesity, type 2 diabetes and metabolic syndrome. It is a progressive form of NAFLD (nonalcoholic fatty liver disease) and is typically characterized by the accumulation of liver fat and extensive inflammatory response. It may progress to liver fibrosis and even cirrhosis and liver cancer.

[0004] For NASH, there is currently only one drug approved by the FDA for clinical use. The current standard treatment method is still mainly exercise and diet, which aims to reduce liver damage through a healthy lifestyle. In this treatment process, the characterization of the degree of NASH progression affects the evaluation of the treatment effect, which has extremely important clinical significance for the treatment of NASH and the development of effective intervention methods for NASH. In addition, NASH usually does not show clinical symptoms before developing severe liver damage, making early diagnostic evaluation difficult to achieve.

[0005] At present, the clinical diagnosis of NASH mainly includes three aspects: pathological evaluation, laboratory examination and imaging examination. Among them, pathological evaluation is the most reliable method. It directly observes fat deposition, inflammation and fibrosis through liver biopsy, and judges the degree of NASH progression by the degree of lesions. Since the judgment process mainly relies on naked eye observation, it has the disadvantage of being difficult to accurately quantify.

[0006] Tertiary lymphoid structures (TLS), also known as the third lymphoid organ or ectopic lymphoid structure, are organized immune cell aggregates produced in non-lymphoid tissues under non-physiological conditions. They generally appear in chronic inflammatory tissues caused by autoimmune diseases, chronic infections, and tumors. TLS mainly contain B cells, follicular dendritic cells (FDC), T cells, fibroblast reticular cells (FRC), stromal cells, dendritic cells, neutrophils, macrophages, and endothelial cells. Among them, follicular dendritic cells (FDC) are usually located in the center of B cells, expressing various receptors, promoting antigen presentation to B cells to express highly active antibodies, while endothelial cells are located at the edge of TLS. The formation and maturation of TLS is a multi-step, dynamic process. In this process, pro-inflammatory signals derived from immune cells act as inducing factors, and activated fibroblasts act as organizers by establishing and maintaining lymphocyte structures or producing key chemokines, recruiting a variety of cells to the corresponding locations. These cells eventually differentiate and mature through extensive cell-to-cell interactions and exert immune effects. Mature TLS includes B cell areas and germinal centers surrounded by T cells. It is an important site for the interaction between tissue cells and immune cells and is closely related to the prognosis of patients with various tumors and the response to immunotherapy.

[0007] The most in-depth research area around TLS is solid tumors. Its regulation of adaptive immunity is considered to be the core of anti-tumor immunity and is considered to be a promising target in solid tumors and immunotherapy. As producers of tumor-specific antibodies, TLS-resident B cells may suppress tumor-specific immunity through mechanisms such as secretion of IL-10. Depending on the antibody isotype produced and the type of immune cells present, tumor-specific antibodies can also inhibit tumor-specific immune responses through signals sent by inhibitory Fc receptors. Although inducing TLS formation or enhancing TLS function may improve anti-tumor immunity, such interventions may also simultaneously enhance autoreactive T and B cell responses in other tissue sites and induce autoimmune toxicity. Although TLS has been found in many tumors, the landmark genes used to define and characterize TLS in different studies are different, making research using the characteristic genes of TLS particularly complicated. Summary of the invention

[0008] The inventors of this application detected and analyzed NASH liver tissues through various techniques such as high-resolution slice scanning, H&E staining, and multi-color immunofluorescence staining, and found that TLS existed in NASH liver tissues, and the distribution of TLS in NASH liver tissues with different degrees of progression was different. Based on this, the inventors speculated that TLS was associated with the course of NASH. On this basis, spatial transcriptome sequencing and bioinformatics analysis were further used to screen out 12 characteristic genes that can characterize NASH-specific TLS, and a NASH-specific TLS gene set was constructed. On this basis, a scoring system for quantifying TLS in individual liver tissues was constructed. Compared with known TLS gene sets in other diseases, the NASH-specific TLS gene set has higher specificity and sensitivity. Combined with the TLS score calculation, it is possible to achieve a quantitative diagnosis of the degree of progression of NASH.

[0009] Based on the above findings, the present invention provides a diagnostic kit for non-alcoholic fatty hepatitis, characterized in that it at least includes a detection object for detecting a characteristic tertiary lymphoid structure gene set of non-alcoholic fatty hepatitis, wherein the characteristic tertiary lymphoid structure gene set of non-alcoholic fatty hepatitis includes the following 12 characteristic genes: IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6 and IGHG3.

[0010] Furthermore, the diagnostic kit provided by the present invention may also have such technical features, wherein the detection object is a combination of any one or more of a detection primer group, a detection probe group, a complementary sequence probe group and a detection antibody group, the detection primer group includes primer pairs for detecting each characteristic gene respectively; the detection probe group includes probes that specifically bind to each characteristic gene respectively; the complementary sequence probe group includes probes that specifically bind to the complementary sequence of each characteristic gene respectively; the detection antibody group includes antibodies that specifically bind to the proteins expressed by each characteristic gene respectively.

[0011] Furthermore, the above detection primer set may also include 12 pairs of primers for detecting the 12 characteristic genes respectively, each pair of primers comprising an F primer and an R primer for detecting the same characteristic gene, and the sequences of the F primers and the R primers in the 12 pairs of primers corresponding to the 12 characteristic genes are shown in SEQ ID NO.1-SEQ ID NO.24, as follows:

[0012]

[0013] In addition, the diagnostic kit provided by the present invention may also include a total RNA extraction reagent, a reverse transcription reagent and / or a sequencing reagent, and the sequencing reagent is a second-generation sequencing reagent or a spatial transcriptome sequencing reagent.

[0014] In addition, the diagnostic kit provided by the present invention may also have such technical features, wherein the detection object is a gene chip, and the gene chip includes a solid phase carrier and a detection antibody or a detection probe fixed on the solid phase carrier and capable of specifically binding to the characteristic gene. In the diagnostic kit, the detection antibody can be connected to an antibody marker, and the antibody marker can be any one or more combinations of enzyme markers, fluorescein markers, isotope markers and biotin markers.

[0015] The present invention also provides a diagnostic system for non-alcoholic fatty liver disease, characterized in that it comprises: a diagnostic kit as described in any of the above items and an analysis device, wherein the analysis device is used to obtain a diagnostic result of non-alcoholic fatty liver disease by analyzing the detection results of characteristic genes.

[0016] Furthermore, the analysis device in the above-mentioned diagnostic system may include: a score calculation unit, which is used to calculate the tertiary lymphatic structure score based on the characteristic tertiary lymphatic structure gene set of non-alcoholic fatty liver disease and the detection results of the characteristic genes using the GSVA algorithm; and a progression degree determination unit, which is used to determine the progression degree of non-alcoholic fatty liver disease as a diagnostic result based on at least the tertiary lymphatic structure score.

[0017] The above-mentioned non-alcoholic fatty liver disease diagnosis system provided by the present invention may further include: an image forming device, used to image the patient's liver tissue staining sample to obtain a sample image; the analysis device also includes an image analysis unit, used to analyze the sample image to obtain the number of tertiary lymphatic structures in the patient's liver, and the progression degree determination unit determines the degree of liver fibrosis based on the number of tertiary lymphatic structures, and the degree of liver fibrosis and the degree of progression of non-alcoholic fatty liver disease are output together as the diagnosis result.

[0018] The present invention also provides a characteristic gene set for non-alcoholic fatty liver disease, characterized in that it includes the following 12 characteristic genes: IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6 and IGHG3.

[0019] According to the diagnostic kit and diagnostic system for non-alcoholic fatty liver disease provided by the present invention, since they include detection objects for detecting 12 characteristic genes IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6 and IGHG3, the expression levels of the 12 characteristic genes can be detected, so that the corresponding TLS scores can be obtained based on the detection results, and the diagnostic results of the degree of progression of non-alcoholic fatty liver disease can be further quantitatively obtained according to the scores; since the 12 characteristic genes have the strongest specificity, the diagnostic results are accurate and effective, and have good clinical application potential. BRIEF DESCRIPTION OF THE DRAWINGS

[0020] Figure 1 These are sample images corresponding to H&E slices of liver tissue samples of mild NASH and severe NASH in Example 1 of the present invention.

[0021] Figure 2 This is a multicolor immunofluorescence staining image of TLS in the NASH liver tissue sample of Example 1 of the present invention.

[0022] Figure 3 This is an immunohistochemical image of TLS in the NASH liver tissue sample of Example 1 of the present invention.

[0023] Figure 4 This is the spatial transcriptome spot map of Example 2 of the present invention.

[0024] Figure 5 Schematic diagram of differential gene set screening in Example 2 of the present invention.

[0025] Figure 6 This is a schematic diagram of the specific gene set screening in Example 2 of the present invention.

[0026] Figure 7 This is a comparison chart of the results of the NASH diagnosis between the scoring system based on the NASH-specific TLS gene set of Example 3 of the present invention and other TLS gene set scoring systems.

[0027] Figure 8 This is a comparison chart of the results of the NASH diagnosis between the scoring system based on the NASH-specific TLS gene set of Example 3 of the present invention and other TLS gene set scoring systems. DETAILED DESCRIPTION

[0028] The specific embodiments of the present invention are described below in conjunction with the examples. In the following examples, the reagents and materials whose sources are not indicated are purchased through conventional commercial channels, and the unindicated operating steps and condition parameters refer to the conventional operations in the art.

[0029] Example 1: Correlation analysis between TLS and NASH

[0030] In this example, liver tissues of different progression degrees collected clinically were used to perform correlation analysis between TLS and NASH, and the Ishak score was used as the diagnostic standard for comparison. The specific process is as follows:

[0031] Liver tissue samples from different liver sites (CV area, S area, PV area) of mild NASH and severe NASH were collected, and each sample was fixed with 4% paraformaldehyde. After tissue dehydration and paraffin embedding, the tissue sections were stained with H&E and scanned with NanoZoomer S360 digital slice scanner to obtain sample images corresponding to the H&E sections.

[0032] Figure 1 These are sample images corresponding to H&E slices of liver tissue samples of mild NASH and severe NASH in Example 1 of the present invention.

[0033] like Figure 1 As shown, TLS exist in different parts of the liver tissues of patients with mild NASH and severe NASH (the parts circled by dotted lines in the figure), and the number of TLS in the liver tissues of patients with severe NASH is generally higher than that of patients with mild NASH.

[0034] In addition, a sample was selected and fixed with 4% paraformaldehyde. After tissue dehydration and paraffin embedding, tissue sections were prepared. Multicolor immunofluorescence staining was performed for T cell CD3 and B cell CD20 to obtain corresponding fluorescent staining samples. Then, Vectra multispectral imager was used to image each fluorescent staining sample and the imaging results were superimposed to obtain the corresponding sample image.

[0035] Figure 2 This is a multicolor immunofluorescence staining image of TLS in a NASH liver tissue sample according to Example 1 of the present invention. The lower side is a CD3 and CD20 fluorescence staining image, and the upper side is a superimposed image of the CD3 and CD20 fluorescence staining images; Figure 3 This is an immunohistochemical image of TLS in the NASH liver tissue sample of Example 1 of the present invention, and the upper side represents CD20 + B cells, the lower side represents CD3 + T cells.

[0036] like Figure 2 , Figure 3 As shown, in NASH liver tissue, TLS manifests as a characteristic aggregated CD3+T cell and CD20+B cell population and is enriched in the vascular area of ​​the liver.

[0037] Example 2: Analysis of NASH-specific TLS gene sets

[0038] In this example, spatial transcriptome sequencing was used to analyze TLS characteristic genes associated with NASH, and the specific process was as follows:

[0039] NASH liver tissue samples of different degrees of liver tissue progression were collected, including NAFLD, mild NASH, NASH severe-1, and NASH severe-2. Each sample was fixed with 4% paraformaldehyde, and the tissue was dehydrated and embedded in paraffin before H&E staining and 10 x Genomics Visium CytAssist were used to evaluate the distribution of TLS in the immune microenvironment of NAFLD and NASH liver tissues.

[0040] Figure 4 This is the spatial transcriptome sequencing spots map of Example 2 of the present invention.

[0041] like Figure 4 As shown in the figure, the liver tissues of NAFLD, mild NASH, NASH severe-1 and NASH severe-2 have different TLS distributions, and with the different degrees of NASH progression, the TLS distribution gradually increases and concentrates, especially enriched in the vascular area.

[0042] Figure 5 is a schematic diagram of differential gene set screening in Example 2 of the present invention, Figure 6 This is a schematic diagram of the specific gene set screening in Example 2 of the present invention.

[0043] like Figure 5 As shown in Figure 2, based on the distribution of different genes in TLS of tissue samples, the top 25 highly expressed differentially expressed genes in TLS regions compared with non-TLS regions were screened to form a preliminary differentially expressed gene set. Figure 6 As shown, the common conditions of each gene in the differential gene set in TLS of NASH liver tissue samples with different progression degrees were further analyzed. Finally, 12 genes were found to be present in TLS of NASH liver tissue samples with different progression degrees, and they can be used as NASH-specific TLS gene set to characterize TLS in NASH liver tissue. The 12 genes included in the NASH-specific TLS gene set are shown in Table 1 below:

[0044] Table 1 NASH-specific TLS gene set

[0045]

[0046] Example 3: Establishment and validation of a scoring system based on a NASH-specific TLS gene set

[0047] This example constructs a TLS scoring system based on the NASH-specific TLS gene set obtained in Example 2, and calculates the TLS score by GSVA. The specific calculation process is as follows:

[0048] First, gene expression profiles were obtained by transcriptome sequencing of liver tissue samples. The Gene Set Variation Analysis (GSVA) ​​(DOI: 10.18129 / B9.bioc.GSVA, version 1.40.1) method was used, and a predefined gene set (i.e., the NASH characteristic TLS gene set mentioned above) was used to evaluate the enrichment score of the gene set. The minimum gene set was set to 5 and the maximum gene set was set to 5000 in the software. The enrichment score of each sample in each gene set was calculated, and finally the enrichment score (i.e., TLS score) matrix was obtained.

[0049] Furthermore, this example uses four transcriptome sequencing data sets related to NASH (the data sets are sourced from the GEO database) to verify the above TLS scoring system. The data sets are as follows:

[0050] ① Non-alcoholic fatty liver disease (NAFLD, GSE151158, n=61);

[0051] ② Non-alcoholic steatohepatitis (NASH, GSE49541, n=104);

[0052] ③ Non-alcoholic steatohepatitis (NASH, GSE207856, n=21);

[0053] ④ Non-alcoholic steatohepatitis (NASH, GSE83596, n=32).

[0054] The verification process is as follows:

[0055] Four NASH-related transcriptome sequencing public datasets were collected, and then GSVA analysis was performed on these datasets based on the above-mentioned TLS gene set consisting of 12 genes, and finally the TLS scores of different groups were obtained.

[0056] Figure 7 3 is a graph showing TLS scoring results of different data sets of the transcriptome sequencing data set of Example 3 of the present invention.

[0057] Figure 7In the figure, AD corresponds to each data set, and each ordinate is a TLS score. The abscissa HD in A represents healthy patients, and NAFLD represents non-alcoholic liver disease; the abscissa NASH-mild in B represents mild non-alcoholic steatohepatitis, and NASH-advanced represents severe non-alcoholic steatohepatitis; the abscissa NC in C represents healthy controls, NAFLD represents non-alcoholic liver disease, and NASH represents non-alcoholic steatohepatitis; the abscissa NC in D represents healthy controls, SS represents fatty liver degeneration, and NASH represents non-alcoholic steatohepatitis.

[0058] like Figure 7 As shown in the figure, compared with the healthy control group, the TLS score was significantly increased in the NAFLD disease group (ie, A) and in the NASH disease progression group (ie, C, D); and compared with the mild NASH group, the increase in the severe NASH group (ie, B) was more obvious, suggesting that the degree of NASH progression can be evaluated by this increase.

[0059] Figure 8 This is a comparison chart of the results of the NASH diagnosis between the scoring system based on the NASH-specific TLS gene set of Example 3 of the present invention and other TLS gene set scoring systems. Figure 8 Among them, 50-gene (i.e., 50 gene set) originated from the TLS gene set characteristic of liver cancer (Sci Adv. 2021 Dec 17;7(51):eabg3750), 39-gene (i.e., 39 gene set) originated from the TLS gene set characteristic of sarcoma (Nat Rev Cancer. 2019 Jun;19(6):307-325), 12-chemokine (i.e., 12 chemokine) originated from the TLS gene set characteristic of breast cancer (J Clin Invest. 2013 Jul;123(7):2873-92), TFH cell-gene (i.e., TFH cell gene set) originated from the TLS gene set characteristic of melanoma (Sci Rep. 2012;2:765), and TH1 / B cell-gene (i.e., TH1 / B cell gene set) originated from the TLS gene set characteristic of gastric cancer (Oncoimmunology. 2015 Jun 3;5(2):e1054598).

[0060] like Figure 8 As shown, compared with the TLS gene sets established for other types of diseases in the prior art (AUC is roughly between 0.5 and 0.65), the NASH-specific TLS gene set of the present invention has the strongest correlation with NASH, that is, it has the strongest NASH diagnostic ability (AUC=0.848).

[0061] Example 4: Diagnostic kit and diagnostic system for non-alcoholic fatty hepatitis

[0062] As described above, the NASH-specific TLS gene set is highly specific to NASH, and therefore, by performing genetic testing and scoring on liver tissue samples of patients to be diagnosed based on this gene set, the degree of NASH progression of the patient to be tested can be determined.

[0063] Based on the above principles, this embodiment provides a diagnostic kit for non-alcoholic fatty liver disease, which is used to detect the NASH characteristic TLS gene set in patient samples. The kit may include detection objects such as detection primers, detection probes, complementary sequence detection probes, and detection antibodies for detecting the 12 characteristic genes in the gene set, and may also include a gene chip with corresponding detection probes or detection antibodies fixed on a solid phase carrier.

[0064] Specifically, a diagnostic system can be formed by using a kit and an analysis device to achieve diagnosis or auxiliary diagnosis of NASH. The kit includes detection primers, total RNA extraction reagents, reverse transcription reagents and / or sequencing reagents for detecting the expression levels of 12 characteristic genes in the NASH characteristic TLS gene set; the analysis device can be a computer with a TLS score calculation program and a progression determination program, which is used to derive the progression of NASH as a diagnostic result based on the test results.

[0065] As an example, based on the above diagnostic system, the process of detecting gene expression level using RT-PCR method is as follows:

[0066] Step S1, total RNA extraction, the specific operation is as follows:

[0067] (1) Place the frozen tissue in liquid nitrogen in a glass homogenizer and crush it. Add Trizol reagent at a ratio of 100 g:3 ml. Homogenize in a glass homogenizer and place on ice for 10-15 min.

[0068] (2) Transfer the tissue suspension into a 1.5 ml EP tube and centrifuge at 13,000 g at 4°C for 10 min.

[0069] (3) Transfer the supernatant to another enzyme-free EP tube and place it at room temperature for 10-15 minutes.

[0070] (4) Add 0.2 ml chloroform / 1 ml Trizol, oscillate for 15 seconds, and let stand at room temperature for 5 minutes.

[0071] (5) Centrifuge at 12000 g for 15 min at 4°C.

[0072] (6) Carefully aspirate the upper aqueous phase and transfer it to a new enzyme-free EP tube.

[0073] (7) Add 0.5 ml isopropanol / 1 ml Trizol, shake, and let stand at room temperature for 10 min.

[0074] (8) Centrifuge at 12000 g for 10 min at 4°C. White flocs will be visible at the bottom of the EP tube.

[0075] (9) Discard the supernatant, dry with paper towels, add 1 ml of 75% ethanol, shake, and thoroughly wash the precipitate.

[0076] (10) Centrifuge at 11000 g for 5 min at 4°C.

[0077] (11) Absorb all ethanol and air dry for 10 minutes (centrifuge to speed up drying and absorb as much liquid as possible).

[0078] (12) When the RNA is translucent, dissolve it in 20 μl of nuclease-free water (mix by pipetting) and freeze at -20°C until needed.

[0079] (13) The extracted total RNA was analyzed for RNA content and purity using a NanoDrop analyzer. The absorbance ratio of all samples at 260 / 280 nm was 1.8-2.0.

[0080] Step S2, reverse transcription reaction, is as follows:

[0081] System composition: DEPC water 9ul, dig primer 1ul, 5×buffer 4ul, 10M dNTPmix 2ul, RNase inhibitor 1ul, total RNA 2ul, reverse transcriptase 1ul, a total of 20ul; the reaction process is 42°C cycle for a total of 60min.

[0082] Step S3, PCR reaction, is as follows:

[0083] System composition: DEPC water 17.5ul, 10×Taq buffer 2.5ul, MgCl2 2.0ul, 10M dNTPMix 0.5ul, upstream primer 0.5ul, downstream primer 0.5ul, Tap enzyme (5u / ul) 0.5ul, CDNA 1.0ul. A total of 25ul.

[0084] PCR instrument parameter settings: 94°C for 5 min, 72°C for 30 s 45 s 2 min.

[0085] Step S4, based on the PCR results, the expression of 12 characteristic genes is calculated, and then the TLS score is calculated by the analysis device through the GSVA algorithm. The degree of progression of NASH is further obtained based on the TLS score, which can be output as a diagnosis result.

[0086] Example 5: Diagnostic system for nonalcoholic steatohepatitis

[0087] The inventors of this application have previously found that TLS is formed in NASH liver tissue through H&E staining and multicolor immunofluorescence staining, and the number of TLS is significantly positively correlated with NASH disease progression. Therefore, this embodiment provides another NASH diagnostic system, which further combines sample staining analysis on the basis of Example 4 to obtain a more accurate diagnostic result.

[0088] Compared with Example 4, the diagnostic system of this embodiment also includes a device for imaging the patient's liver tissue staining sample to obtain a sample image, and the analysis device may further include an image analysis unit, which analyzes the sample image to obtain a TLS analysis result. Based on the TLS score obtained in Example 4, further combined with the TLS analysis result, a more accurate NASH diagnosis result can be obtained.

[0089] Specifically, based on Example 4, this example further uses H&E staining and mIHC (multicolor immunofluorescence staining) to process liver tissue samples to obtain H&E staining samples and mIHC staining samples, and the operation is as follows:

[0090] (I) Tissue embedding

[0091] (1) Sampling: Fresh tissue is fixed in 4% paraformaldehyde for more than 24 hours. Take the tissue out of the fixative and place it in a fume hood. Use a scalpel to trim the target area and place the trimmed tissue and the corresponding label in a dehydration box.

[0092] (2) Dehydration: Place the dehydration box in the hanging basket and dehydrate in the dehydrator with graded alcohols. 75% alcohol for 4 hours - 85% alcohol for 2 hours - 90% alcohol for 2 hours - 95% alcohol for 1 hour - anhydrous ethanol I for 30 minutes - anhydrous ethanol II for 30 minutes - alcohol benzene for 5-10 minutes - xylene I for 5-10 minutes - xylene II for 5-10 minutes - wax I for 1 hour - wax II for 1 hour - wax III for 1 hour.

[0093] (3) Embedding: Embed the wax-soaked tissue in an embedding machine. First, place the melted wax into the embedding frame. Before the wax solidifies, take the tissue out of the dehydration box and place it in the embedding frame according to the requirements of the embedding surface and attach the corresponding label. Cool in a -20℃ freezer. After the wax solidifies, take the wax block out of the embedding frame and trim the wax block.

[0094] (4) Sectioning: Place the trimmed wax block on a paraffin slicer and slice it to a thickness of 4 μm. Float the slices on the 40°C warm water of the slicer to flatten the tissue, pick up the tissue with a slide, and place it in a 60°C oven to bake. After the water is dried and the wax is melted, take it out and store it at room temperature for later use.

[0095] 2. H&E staining

[0096] (1) Dewaxing: xylene 10 min - xylene 10 min - anhydrous ethanol 5 min - anhydrous ethanol 5 min - 95% ethanol 5 min - 85% ethanol 5 min - 70% ethanol 5 min - pure water 5 min.

[0097] (2) Staining: Hematoxylin for 4 min - rinse with tap water for 10 min - hydrochloric acid ethanol differentiation for 3 s - rinse with tap water for 10 min (return to blue) - eosin for 25 s - 1 min.

[0098] (3) Dehydration: anhydrous ethanol for 5 min-anhydrous ethanol for 5 min-anhydrous ethanol for 5 min.

[0099] (4) Permeabilization: xylene 10 min-xylene 10 min-xylene 10 min.

[0100] (5) Sealing: After sealing with neutral resin, wait for it to dry naturally and then place it under a microscope for observation and photography.

[0101] 3. mIHC method (multicolor immunofluorescence staining)

[0102] (1) Baking: Bake the slices in a constant temperature oven at 60-65°C for more than 30 minutes.

[0103] (2) Dewaxing and hydration: The sections were placed in xylene No. 1 for 10 min, xylene No. 2 for 8 min, anhydrous ethanol for 5 min, 90% ethanol for 3 min, 80% ethanol for 3 min, and 70% ethanol for 3 min. The sections were then rinsed in DDH2O twice, each time for 3 min.

[0104] (3) Antigen retrieval: Heat the sodium citrate buffer / Ph 6.0 in a microwave oven until it is boiled. Place the slices in the slice rack and continue heating and boiling for 10 minutes. Allow to cool naturally to room temperature. After cooling, place the slices on a shaker and rinse twice with ddH2O for 3 minutes each time; rinse twice with TBST solution for 3 minutes each time.

[0105] (4) Add 3% hydrogen peroxide solution: wipe off the water droplets around the tissue with absorbent paper, draw a circle around the tissue with an immunohistochemistry pen, and then add 3% hydrogen peroxide solution. Incubate at room temperature in the dark for 15 min. After incubation, rinse twice with TBST solution, each time for 3 min.

[0106] (5) Blocking: Shake off the water, absorb the residual solution, add the multicolor kit blocking diluent and block for 20 minutes.

[0107] (6) Primary antibody incubation: Dilute the primary antibody with the blocking diluent of the multicolor kit, add an appropriate amount of primary antibody solution to the sliced ​​tissue, completely cover the tissue, and incubate in a humidified chamber at room temperature for 1 hour. After the incubation, rinse off the primary antibody solution with a rinse bottle and rinse with TBST solution twice, 3 minutes each time.

[0108] (7) Secondary antibody incubation: Add an appropriate amount of the mixed secondary antibody solution of mouse and rabbit in the multicolor kit to the tissue sections and incubate in a humidified chamber at room temperature for 30 min. Rinse off the secondary antibody solution with a rinse bottle and rinse with TBST solution twice, 3 min each time.

[0109] (8) Opal dye: Shake off the water, absorb the residual water, add the prepared opal reagent working solution, incubate at room temperature in the dark for 10 min; rinse with TBST solution twice, 3 min each time.

[0110] (9) Boil sodium citrate buffer (pH 6.0) in a microwave at high heat for 2 minutes. Place the slices on a slice rack and immerse them in the boiling sodium citrate buffer. Microwave at low heat for 10 minutes and cool naturally to room temperature. After cooling, place the slices on a shaker and rinse them twice in ddH2O for 3 minutes each time; rinse them twice in TBST solution for 3 minutes each time.

[0111] (10) Referring to the TLS panel staining sequence shown in Table 2 below, each primary antibody and the above-mentioned mixed secondary antibody solution are used for incubation and staining in turn, and steps 7) to 9) are repeated until the last round of secondary antibody incubation is completed.

[0112] Table 2. TLS panel staining sequence

[0113]

[0114] (11) Opal 780 dye: Shake off the water, absorb the residual water, add the prepared Opal reagent working solution, incubate at room temperature in the dark for 1 hour; rinse twice with TBST solution, 3 minutes each time.

[0115] (12) DAPI nuclear staining: Add an appropriate amount of DAPI working solution to the tissue section to completely cover the tissue and incubate in a humidified box at room temperature in the dark for 5-10 min; rinse twice with TBST solution, 3 min each time; rinse with ddH2O for 3 min.

[0116] (13) Sealing and storage: Shake off the water, absorb the residual water, add water-soluble anti-extraction sealing agent to seal the slides, store at 4°C away from light and take pictures.

[0117] After obtaining the H&E staining sample and the mIHC staining sample through the above steps, the H&E staining sample is imaged and scanned using the NanoZoomer S360 digital slice scanner, and the mIHC staining sample is imaged using the Vectra multispectral imager, and the number of TLS in the liver tissue sample is statistically analyzed using image analysis and recognition methods. Then, the analysis device is used to combine the TLS number result and the TLS score of Example 4 to obtain a diagnostic result for output, and the diagnostic result is specifically determined by the following method:

[0118] For patients clinically suspected of NASH, if the TLS score in the tissue obtained by liver puncture biopsy is higher than 1.1632, it is considered to be diagnosed with severe NASH; if it is lower than 1.1632, it is considered to be mild NASH or undiagnosed.

[0119] For patients with clinically confirmed NASH, the liver biopsy tissue was 2 When the number of TLS in the area is 0, liver fibrosis can be ruled out; when the number of TLS is 1-2, NASH with mild fibrosis is considered; when the number of TLS is 3-4, NASH with severe fibrosis is considered; when the number of TLS is greater than 5, NASH combined with cirrhosis is considered.

Claims

1. A diagnostic kit for non-alcoholic fatty hepatitis, characterized in that: At least one test for detecting a set of tertiary lymphoid structural genes characteristic of nonalcoholic steatohepatitis, Among them, the characteristic tertiary lymphoid structure gene set of non-alcoholic fatty liver disease is composed of the following 12 characteristic genes: IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6, and IGHG3.

2. The diagnostic kit for non-alcoholic steatohepatitis according to claim 1, characterized in that: in, The detection object is any one or more combinations of a detection primer set, a detection probe set, a complementary sequence probe set, and a detection antibody set. The detection primer set comprises primer pairs for detecting each of the characteristic genes respectively; The detection probe group comprises probes that specifically bind to each of the characteristic genes; The complementary sequence probe group comprises probes that specifically bind to the complementary sequences of the characteristic genes respectively; The detection antibody group comprises antibodies that specifically bind to proteins expressed by each of the characteristic genes.

3. The diagnostic kit for non-alcoholic steatohepatitis according to claim 1, characterized in that: in, The detection object is a gene chip, which includes a solid phase carrier and a detection antibody or a detection probe fixed on the solid phase carrier and capable of specifically binding to the characteristic gene.

4. The diagnostic kit for non-alcoholic steatohepatitis according to claim 3, characterized in that: in, The detection antibody is connected to an antibody marker, and the antibody marker is any one or more combinations of enzyme markers, fluorescent markers, isotope markers and biotin markers.

5. A diagnostic system for non-alcoholic fatty hepatitis, characterized in that: include: The diagnostic kit and the analytical device according to any one of claims 1 to 4, The analysis device is used to analyze the detection results of the characteristic genes to obtain a diagnosis result of non-alcoholic fatty hepatitis.

6. The diagnostic system for nonalcoholic steatohepatitis according to claim 5, Features: Wherein, the analysis device comprises: A score calculation unit, for calculating the tertiary lymphatic structure score based on the characteristic tertiary lymphatic structure gene set of non-alcoholic steatohepatitis and the detection results of the characteristic genes by using the GSVA algorithm; and The progression degree determination unit is used to determine the progression degree of non-alcoholic fatty hepatitis as the diagnosis result at least according to the three-level lymphatic structure score.

7. The diagnostic system for nonalcoholic steatohepatitis according to claim 6, characterized in that: Also includes: An image forming device, used to image the patient's liver tissue staining sample to obtain a sample image; The analysis device further comprises an image analysis unit for analyzing the sample image to obtain the number of tertiary lymphatic structures in the patient's liver. The progression degree determination unit determines the degree of liver fibrosis based on the number of the tertiary lymphatic structures, and the degree of liver fibrosis and the progression degree of the non-alcoholic steatohepatitis are output together as the diagnosis result.

8. A characteristic gene set for non-alcoholic fatty liver disease, characterized in that: It is composed of the following 12 characteristic genes: IGHG1, PTGDS, IGKC, IGHA1, JCHAIN, IGHM, VIM, MGP, CCL19, C7, S100A6, and IGHG3.